VYNE Therapeutics Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2016 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
VYNE Therapeutics Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2016 to Q2 2024.
  • VYNE Therapeutics Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$9.41M, a 6.48% increase year-over-year.
  • VYNE Therapeutics Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$28.4M, a 19% increase year-over-year.
  • VYNE Therapeutics Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$28.5M, a 22.6% decline from 2022.
  • VYNE Therapeutics Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$23.2M, a 68.3% increase from 2021.
  • VYNE Therapeutics Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$73.3M, a 71.3% increase from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$28.4M -$9.41M +$652K +6.48% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 -$29.1M -$6.25M -$627K -11.2% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 -$28.5M -$6.19M +$3.76M +37.8% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-01
Q3 2023 -$32.2M -$6.58M +$2.88M +30.4% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-13
Q2 2023 -$35.1M -$10.1M -$1.58M -18.7% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 -$33.5M -$5.62M -$10.3M -220% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 -$23.2M -$9.95M +$1.63M +14% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-01
Q3 2022 -$24.8M -$9.46M +$11.8M +55.6% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 -$36.7M -$8.48M +$11.4M +57.5% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 -$48.1M $4.67M +$25.2M Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 -$73.3M -$11.6M +$11.6M +50.1% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-14
Q3 2021 -$84.9M -$21.3M +$3.43M +13.9% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$88.4M -$19.9M +$148M +88.1% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-12
Q1 2021 -$236M -$20.6M +$19.7M +48.9% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 -$256M -$23.2M -$1.68M -7.83% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-17
Q3 2020 -$254M -$24.7M -$1.55M -6.71% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 -$252M -$167M -$148M -782% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
Q1 2020 -$104M -$40.2M -$25M -165% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 -$78.9M -$21.5M -$3.9M -22.2% Oct 1, 2019 Dec 31, 2019 10-K 2020-03-03
Q3 2019 -$75M -$23.2M -$10.3M -80.3% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 -$64.6M -$19M -$10.6M -128% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 -$54M -$15.2M -$2.55M -20.1% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-11
Q4 2018 -$51.4M -$17.6M -$8.32M -89.7% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-03
Q3 2018 -$43.1M -$12.8M -$4.68M -57.2% Jul 1, 2018 Sep 30, 2018 10-K 2020-03-03
Q2 2018 -$38.5M -$8.35M -$2.19M -35.7% Apr 1, 2018 Jun 30, 2018 10-K 2020-03-03
Q1 2018 -$36.3M -$12.7M -$7.18M -131% Jan 1, 2018 Mar 31, 2018 10-K 2020-03-03
Q4 2017 -$29.1M -$9.28M -$4.44M -91.8% Oct 1, 2017 Dec 31, 2017 10-K 2019-02-28
Q3 2017 -$24.6M -$8.17M -$4.77M -140% Jul 1, 2017 Sep 30, 2017 10-K 2019-02-28
Q2 2017 -$19.9M -$6.15M -$2.59M -72.7% Apr 1, 2017 Jun 30, 2017 10-K 2019-02-28
Q1 2017 -$17.3M -$5.47M -$3.2M -141% Jan 1, 2017 Mar 31, 2017 10-K 2019-02-28
Q4 2016 -$14.1M -$4.84M Oct 1, 2016 Dec 31, 2016 10-K 2018-03-28
Q3 2016 -$3.4M Jul 1, 2016 Sep 30, 2016 10-K 2018-03-28
Q2 2016 -$3.56M Apr 1, 2016 Jun 30, 2016 10-K 2018-03-28
Q1 2016 -$2.27M Jan 1, 2016 Mar 31, 2016 10-K 2018-03-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.